“While current approaches aim to target the location of stimulation to the brain, this approach is targeting the timing of stimulation by delivering it during sleep,” said
Dustin Heldman, principal investigator and biomedical research manager.
Because the device method works while the patient is sleeping, it should limit patient discomfort while maybe targeting brain states likely to improve motor symptoms, according to the company.
The phase 1 clinical study for this method is ongoing.
Brian Kolkowski, EVP and general counsel at GLNT, said a growing patent portfolio that protects technology in the company’s targeted markets provides a strategic advantage.
Movement disorders, especially Parkinson’s, have been a large focus of GLNT, which also deals with telehealth and physiological monitoring for research and education.
Read more: http://medcitynews.com/2013/07/glnt-receives-another-patent-to-treat-parkinsons-this-time-for-deep-brain-stimulating-method-delivered-while-patient-snoozes/#ixzz2zLylIRYM
No comments:
Post a Comment